Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial (Recipients/Patients):
- People who have been diagnosed with a blood cancer confirmed by laboratory testing, including certain types of leukemia, lymphoma, myeloma, or related blood disorders that meet standard medical criteria for a stem cell transplant from a donor.
- People aged 60 to 85 years old, or people aged 18 to 60 who are considered by their doctors to be unsuitable for the most intensive type of transplant preparation (for reasons such as previous transplants, organ function concerns, significant other health conditions, physical frailty, or low performance scores).
- People who have at least one suitable donor available — either a matching or partially matching family member, or an unrelated donor.
- People with a general health/performance score of 60 or above on the Karnofsky scale (a medical measure of how well a person can carry out daily activities — confirm with trial site).
- People who are able to understand the study and are willing to sign a consent form.
- People whose heart, lungs, kidneys, and liver are functioning at levels that meet the trial's minimum requirements (confirm specific values with trial site).
- People who are not pregnant, and who agree to use adequate contraception for at least one year after transplant. Women of childbearing potential must have a negative pregnancy test within 7 days before enrolling.
Who may not be able to join (Recipients/Patients):
- People who are currently taking part in another clinical trial using an experimental treatment, or whose previous experimental treatment was completed less than 2 weeks before starting the trial's preparation stage.
- People whose blood cancer is not well enough controlled — for example, leukemia that has not reached remission, or lymphoma that has not responded at least partially to prior treatment.
- People with another serious illness that, in the opinion of the treating doctor, would make it unsafe to go ahead with a transplant.
- People who are currently breastfeeding, as the potential effects of the study medications on a nursing infant are unknown.
- People who also have a non-blood cancer that has spread to other parts of the body, has not responded to treatment, cannot be treated with curative intent, or was treated with curative intent within the last 2 years — with the exception of certain common skin cancers.
Who might be able to join this trial (Donors):
- Related donors aged 12 and older, and unrelated donors aged 18 and older, who are assessed as eligible through the appropriate medical and regulatory review process and who are willing to provide research samples.
Who may not be able to join (Donors):
- No specific exclusion criteria have been listed for donors in this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christopher G Kanakry, M.D., National Cancer Institute (NCI)
Phone: (240) 858-3755
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
determine if optimal dose of PTCy to prevent grade III-IV acute GVHD (aGVHD) at day +60
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.